These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 17904317

  • 1. Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size.
    Yamauchi M, Kusano H, Saito E, Abe M, Tsutsumi K, Uosaki Y, Nakakura M, Kato Y, Aoki N.
    Int J Pharm; 2008 Mar 03; 351(1-2):250-8. PubMed ID: 17904317
    [Abstract] [Full Text] [Related]

  • 2. Reducing the impact of binding of UCN-01 to human alpha1-acid glycoprotein by encapsulation in liposomes.
    Yamauchi M, Kusano H, Nakakura M, Kato Y.
    Biol Pharm Bull; 2005 Jul 03; 28(7):1259-64. PubMed ID: 15997110
    [Abstract] [Full Text] [Related]

  • 3. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding.
    Hedaya MA, Daoud SS.
    Anticancer Res; 2001 Jul 03; 21(6A):4005-10. PubMed ID: 11911284
    [Abstract] [Full Text] [Related]

  • 4. Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein.
    Katsuki M, Chuang VT, Nishi K, Suenaga A, Otagiri M.
    Pharm Res; 2004 Sep 03; 21(9):1648-55. PubMed ID: 15497692
    [Abstract] [Full Text] [Related]

  • 5. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein.
    Fuse E, Hashimoto A, Sato N, Tanii H, Kuwabara T, Kobayashi S, Sugiyama Y.
    Pharm Res; 2000 May 03; 17(5):553-64. PubMed ID: 10888307
    [Abstract] [Full Text] [Related]

  • 6. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.
    Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, Kuwabara T, Kobayashi S, Sugiyama Y.
    Cancer Res; 1999 Mar 01; 59(5):1054-60. PubMed ID: 10070963
    [Abstract] [Full Text] [Related]

  • 7. Use of photoaffinity labeling and site-directed mutagenesis for identification of the key residue responsible for extraordinarily high affinity binding of UCN-01 in human alpha1-acid glycoprotein.
    Katsuki M, Chuang VT, Nishi K, Kawahara K, Nakayama H, Yamaotsu N, Hirono S, Otagiri M.
    J Biol Chem; 2005 Jan 14; 280(2):1384-91. PubMed ID: 15509559
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
    Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK.
    J Clin Oncol; 2005 Mar 20; 23(9):1875-84. PubMed ID: 15699481
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
    Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S.
    Cancer Res; 1998 Aug 01; 58(15):3248-53. PubMed ID: 9699650
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01.
    Landin EJB, Williams C, Ryan SA, Bochel A, Akter N, Redfield C, Sessions RB, Dedi N, Taylor RJ, Crump MP.
    J Biol Chem; 2021 Dec 01; 297(6):101392. PubMed ID: 34758357
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. On the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding.
    Tang H, Mayersohn M.
    J Clin Pharmacol; 2006 Apr 01; 46(4):398-400. PubMed ID: 16554445
    [Abstract] [Full Text] [Related]

  • 15. Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis.
    Haeri A, Sadeghian S, Rabbani S, Anvari MS, Boroumand MA, Dadashzadeh S.
    Int J Pharm; 2011 Jul 29; 414(1-2):16-27. PubMed ID: 21554939
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.